Less than three weeks after a Texas judge tossed a lawsuit by industry lobbying group PhRMA which challenged the ...
In the latest shake-up amid waves of changes at Bayer, the company is planning to add new expertise to its board room, ...
Moderna is laying off employees within its manufacturing unit, with the move tied to a resizing of its COVID production work.
North Carolina has proved an attractive destination for biopharma companies large and small in recent years, ginning up ...
Deerfield Agency has made another new hire, appointing the “growth-oriented” Eric Steckelman to lead its business development ...
BeiGene expanded its global workforce by 1,400 over the past 12 months amid fast revenue growth. | BeiGene expanded its ...
In what CEO Albert Bourla called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new ...
Several months after Societal CDMO launched a restructuring campaign that led to 26 layoffs, the small molecule contract ...
Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry.
The warning from the national public health agency comes after one of the two providers of tetanus shots in the U.S., MassBiologics, discontinued production of its tetanus and diphtheria vaccine.
Despite a restricted FDA label, Sarepta Therapeutics has seen early commercial success with its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. This year, the company aims to dramatically ...
For the second time in four weeks, GSK has settled a personal injury lawsuit in California state court over the heartburn ...